HHS opens a limited compounding path for six peptides — including mitochondria-derived MOTS-c — without FDA approval

Edited by Samael A. Tejada, Founder & Editor-in-Chief

This is the document the peptide debate has been building toward since the summer advisory vote: not an approval, not a listing, but a written decision to look the other way — for six named substances, by named routes, under named conditions. For MOTS-c, the peptide your mitochondria's own genome encodes, that distinction is the whole story.

What exactly did HHS publish?

A draft 'Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances,' filed October 28 and published in the Federal Register on October 30, 2026 (91 FR 68526). In the policy's own words, HHS 'does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician compounding a drug product using a peptide bulk drug substance found in Appendix A' while the 503A bulks list 'is developed through rulemaking.' The six substances are BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500 — emideltide, the seventh peptide from the July advisory process, is not among them. Each carries specified identities and routes: MOTS-c acetate and TB-500 acetate by subcutaneous or intramuscular injection only; BPC-157 acetate by subcutaneous, intramuscular, oral or topical routes; Epitalon acetate by subcutaneous or intramuscular injection in intermittent courses; Semax free base intranasally only; KPV acetate topically or orally only.

What conditions come with the discretion?

The discretion holds only inside a fence of conditions described in the policy and summarized in law-firm analyses of it: the substance, salt form and route must match the appendix; bulk material must come from an FDA-registered facility with a valid certificate of analysis; the original manufacturer must be FDA-registered and compliant with current good manufacturing practice; serious adverse events must be reported to FDA MedWatch; the product must be labeled 'This is a compounded drug product. Not for resale.'; only a single active ingredient is covered (blends fall outside the policy, per November 2 follow-up analysis); oral products need documentation of adequate human bioavailability; the only co-packaged device covered is an FDA 510(k)-cleared syringe; and compounding must be against a patient-specific prescription, as section 503A requires. Step outside the fence — a different route, a blend, a non-registered source — and the discretion does not apply.

What does this not do?

Almost everything a headline might claim for it. It does not add any peptide to the 503A bulks list, which still requires rulemaking. It does not make any compounded peptide FDA-approved — the policy itself states that compounded drugs are not FDA-approved, and none of the six meets the standard eligibility routes (a USP/NF monograph, being a component of an FDA-approved drug, or an existing listing). It creates no legal rights: the text says the policy 'does not establish any rights for any person and is not binding on HHS or the public,' and HHS reserves the ability to revisit it, in whole or in part, if a safety signal or product-quality issue arises. And it says nothing new about whether these peptides work: the clinical evidence for MOTS-c and the others remains early and thin, which is why this page's evidence labels below separate the regulatory fact (established) from the therapeutic claims (preliminary at best). Comments on the draft policy close at 11:59 PM Eastern on November 13, 2026.

Where the evidence stands

• Established: The regulatory facts: HHS published the draft enforcement-discretion policy in the Federal Register on October 30, 2026 (91 FR 68526, Doc. 2026-22192), covering BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500 under specified identities, routes and conditions while the 503A bulks list is developed; compounded drugs are not FDA-approved; and the policy states it creates no rights and may be revisited if a safety signal arises. Comments close November 13, 2026.
• Preliminary: The therapeutic evidence for the six peptides, including mitochondria-derived MOTS-c, remains early — largely preclinical or small-scale human data — and none of the six has an FDA-approved product or an established efficacy record for the uses they are commonly marketed for.
• Absent: Any FDA approval, any completed 503A bulks-list rulemaking for these substances, and long-term safety data for compounded peptide use at scale.